Search results
Results from the WOW.Com Content Network
Excessive use may result in medication overuse headaches. [3] Use is not recommended during pregnancy and breastfeeding is not recommended within 24 hours after taking a dose. [4] Rizatriptan is in the triptan class and is believed to work by activating the 5-HT 1 receptor. [3] Rizatriptan was patented in 1991 and came into medical use in 1998.
The triptan drug class includes 1st generation sumatriptan (which has poor bioavailability), and second generation zolmitriptan. [2] Due to their safety, efficacy and selectivity, triptans are considered first line agents for abortion of migraines. [2]
The term for individuals taking five or more medications is polypharmacy, which commonly occurs in elderly people, increasing their risk of overmedication. [10] Medical providers are generally hesitant to prescribe polypharmacy in the elderly due to the risk of harmful drug interactions.
Triptans are a family of tryptamine-based drugs used as abortive medication in the treatment of migraines and cluster headaches. This drug class was first commercially introduced in the 1990s. This drug class was first commercially introduced in the 1990s.
Eletriptan, sold under the brand name Relpax and used in the form of eletriptan hydrobromide, is a second-generation triptan medication intended for treatment of migraine headaches. [3] [4] It is used as an abortive medication, blocking a migraine attack which is already in progress. Eletriptan is marketed and manufactured by Pfizer Inc.
As with other triptans, almotriptan should not be used in patients with a history, symptoms or signs of ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal's angina) or severe hypertension and uncontrolled mild or moderate hypertension.
Zolmitriptan is a triptan and a substituted tryptamine. [ 3 ] [ 4 ] It is specifically the derivative of N , N -dimethyltryptamine (DMT) in which the hydrogen atom at position 5 of the indole ring has been substituted with a [(4 S )-2-oxo-1,3-oxazolidin-4-yl]methyl group .
In 1991, Glaxo received approval for sumatriptan, which was the first available triptan. In July 2009, the US FDA approved a single-use jet injector formulation of sumatriptan. The device delivers a subcutaneous injection of sumatriptan, without the use of a needle. Autoinjectors with needles have been previously available in Europe and North ...